



P&T COMMITTEE MEETING

Agenda

July 8, 2014

1:00 p.m. – 5:00 p.m.

225 E. 16th Ave, 1st Floor Conference Room, Denver, CO

☐ **Committee Member Introductions**

Unfinished Business and General Orders

- ☐ Approval of minutes for the April 8, 2014 meeting
- ☐ Update on Newer generation antihistamines and combinations
- ☐ Update on angiotensin receptor blockers
- ☐ Update on renin inhibitors and combinations
- ☐ Update on fibromyalgia agents
- ☐ Update on testosterone products
- ☐ Update on long acting oral opioids
- ☐ Update on inhaled anticholinergics and combinations
- ☐ Update on inhaled beta 2 agonists
- ☐ Update on long acting beta 2 agonists
- ☐ Update on inhaled corticosteroids and combinations
- ☐ Update on skeletal muscle relaxants
- ☐ Update on topical immunomodulators

New Business

1. Updates from the Prior Authorization Call Center

2. Drug Classes Up for Review:

Each Review will contain public testimony, class updates and market share, and Committee discussion:

- ☐ Review of Hepatitis C Agents
- ☐ Review of Oral Anticoagulants
- ☐ Review of Biphosphonates
- ☐ Review of Oral Biguanides
- ☐ Review of Hypoglycemic Combinations
- ☐ Review of Meglitinides
- ☐ Review of Newer Diabetic Agents
- ☐ Review of Thiozolidinediones
- ☐ Review of Erythropoiesis Stimulating Agents
- ☐ Review of Overactive Bladder Agents
- ☐ Review of Stimulants and other ADHD

Each Review will contain:

- Drug class Overview and Agents up for review for each Drug Class

- Oral presentation by manufacturers, providers, and public following overview
- Committee Discussion and Recommendations for each Class

Upcoming Meeting Date: Tuesday, October 7, 2014; 1:00 p.m. – 5:00 p.m.

Interested parties who want to present at the meeting are encouraged to give advanced notice. Please contact Swaniece Grubb at 303-866-3614 or by email at Swaniece.grubb@state.co.us. Written public comments can be submitted to pdl@state.co.us and will be distributed to all present P&T Committee Members.